Protheragen-ING Lab specializes in providing comprehensive macromolecule development services to support your drug discovery and development efforts. Our team of experienced scientists and researchers is dedicated to delivering high-quality solutions tailored to meet your specific needs. Partner with us to unlock the full potential of macromolecules and accelerate your journey toward successful drug development.
The curtain opens on macromolecules!
Macromolecules, also known as biologics, are complex molecules typically derived from living organisms such as animals or microorganisms. They differ from small molecules, which are chemically synthesized compounds with a defined structure.
Vaccines, blood and blood components, allergies, somatic cells, gene treatments, tissues, and recombinant therapeutic proteins are only a few examples of the wide range and diversity of biological products. Prompt use of biologics may provide the most effective means of treating a variety of diseases and conditions for which no other treatment options exist.
Comprehensive large molecule development services
Protheragen-ING Lab is dedicated to delivering high-quality solutions for the development and optimization of large molecules, including monoclonal antibodies, recombinant proteins, and other biologics. With our state-of-the-art facilities and cutting-edge technologies, we are committed to accelerating your drug discovery and development process while ensuring regulatory compliance and product quality.
Our process research and development services encompass both upstream and downstream activities, tailored to meet your specific project requirements. We have expertise in cell line development, fermentation optimization, bioreactor scale-up, and purification process development. Our scientists employ advanced techniques and analytical methods to optimize productivity, yield, and product quality, ensuring the scalability and efficiency of your large molecule production.
We offer comprehensive developability analysis and method development services to assess the feasibility and suitability of your candidate molecules for further development. Our experts leverage a range of techniques, including structural analysis, thermal stability assessment, and formulation studies, to evaluate critical parameters such as solubility, aggregation propensity, and stability. By identifying potential challenges and optimizing molecule characteristics early in the development process, we help mitigate risks and enhance the success rate of your large molecule programs.
Our druggability evaluation services focus on assessing the druggability of your target proteins, considering factors such as post-translational modifications, protein physical and chemical properties, and molecular stability. Through a combination of computational modeling, structural analysis, and experimental studies, we provide valuable insights into target selection, optimization, and lead identification. Our goal is to enable the development of therapeutically relevant large molecules with improved efficacy and pharmacokinetic properties.
Examples of biologics considered large molecules
- Monoclonal Antibodies (mAbs): Adalimumab (Humira), rituximab (Rituxan), and trastuzumab (Herceptin).
- Recombinant Proteins: Erythropoietin (EPO), insulin, and growth factors like granulocyte colony-stimulating factor (G-CSF) and erythropoietin-stimulating agents (ESAs).
- Fusion Proteins: Examples include etanercept (Enbrel), a fusion protein used to treat rheumatoid arthritis, and abatacept (Orencia), a fusion protein used for the treatment of autoimmune diseases.
- Antibody-Drug Conjugates (ADCs): Ado-trastuzumab emtansine (Kadcyla) and brentuximab vedotin (Adcetris).
- Therapeutic Enzymes: Examples include asparaginase used in the treatment of acute lymphoblastic leukemia (ALL) and recombinant coagulation factors used in the management of bleeding disorders.
- Vaccines: Recombinant protein-based vaccines like the human papillomavirus (HPV) vaccine and the hepatitis B vaccine.
- Gene Therapies: Viral vector-based gene therapies like Luxturna for inherited retinal diseases and Zolgensma for spinal muscular atrophy.
Contact us today to learn more about how we can accelerate your biologics programs and bring your innovative therapies to patients in need.